Comparing Eloxx Pharmaceuticals (ELOX) and Its Peers

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ competitors have a beta of -3.17, indicating that their average stock price is 417% less volatile than the S&P 500.

Insider & Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Eloxx Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.76
Eloxx Pharmaceuticals Competitors	$17.90 billion	$3.15 billion	551.14

Eloxx Pharmaceuticals’ competitors have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Eloxx Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7616	13668	25502	1003	2.42

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, suggesting a potential upside of 131.34%. As a group, “Pharmaceuticals” companies have a potential upside of 28.40%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Eloxx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.23%	-223.52%	-16.98%

Summary

Eloxx Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.